1-3 of 3
Hongli Zheng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial

Xiangyu Zhao, Meng Lv, Yu Wang, Yi-Yang Ding, Zhixiao Zhou, Jiasheng Wang, HongLi Zheng, Xueqiang Zhao, Xin Lin, Xiao Jun Huang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4831.
https://doi.org/10.1182/blood-2024-207297
Published: 2024
Journal Articles

A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Xingyu Cao, Guangna Liu, Jianping Zhang, Yanli Zhao, Hua Chen, Hongli Zheng, Wei Rui, Lemei Jia, Xueqiang Zhao, Xin Lin, Peihua Lu
Journal: Blood
Blood (2021) 138 (Supplement 1): 3848.
https://doi.org/10.1182/blood-2021-146446
Published: 2021
Journal Articles

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Jiasheng Wang, Yue Liu, Junfang Yang, Jingjing Li, Gailing Zhang, MD, Yanze Shi, Jiujiang He, Dan Song, Wenqian Li, Shulian Xia, Min Zhang, Zhixiao Zhou, Lemei Jia, Hongli Zheng, Xin Lin, Peihua Lu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-136833
Published: 2020